IFP Advisors’s Inozyme Pharma INZY Stock Holding History

IFP Advisors’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$2	–	4082
2025 Q1	$1	Hold	1	–	–	﹤0.01%	4291
2024 Q4	$3	Buy	+1	New	+$4	﹤0.01%	4573

Other funds holding INZY

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

IFP Advisors's INZY Position: Q2 2025 in Review

IFP Advisors sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 1 share — an estimated $2 sold.

IFP Advisors first reported a position in INZY in Q4 2024 and held it in 2 quarters. The position peaked at $3 in Q4 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

IFP Advisors reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
IFP Advisors sold 1 Inozyme Pharma share in Q2 2025, an estimated $2.
IFP Advisors first reported a position in Inozyme Pharma in Q4 2024 and held it in 2 quarters.
IFP Advisors's Inozyme Pharma position peaked at $3 in Q4 2024.
86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on IFP Advisors's 13F filing for Q2 2025, filed 24 Jul 2025.